Across life sciences, the brightest minds are buried in busywork. Regulatory strategists, medical writers, quality and safety experts – people trained to bring therapies to market – are still spending most of their time formatting documents, managing version control, and stitching together fragmented tools.

在生命科学领域，最聪明的人才却埋头于繁琐的工作。监管策略师、医学撰稿人、质量与安全专家——这些受过将疗法推向市场训练的人们，仍然将大部分时间花在格式化文档、管理版本控制和拼接碎片化的工具上。

LogicFlo AI, the company building the AI agent workforce for life sciences, is changing that..

LogicFlo AI，这家为生命科学领域构建AI代理劳动力的公司，正在改变这一现状。

The Boston-based startup today announces a $2.7 million seed funding round to scale its intelligent agent platform across the pharmaceutical, biotech, and medtech industries. The round was led by Lightspeed with participation from leading healthcare and enterprise AI investors. It will fund product expansion, team growth, and deeper deployments with global life sciences organizations, including a Fortune 500 customer already under contract..

总部位于波士顿的这家初创公司今天宣布了一轮 270 万美元的种子轮融资，用于将其智能代理平台扩展到制药、生物技术和医疗技术行业。本轮融资由 Lightspeed 领投，多家领先的医疗保健和企业人工智能投资者参与。这笔资金将用于产品扩展、团队增长，以及与全球生命科学组织的深度部署合作，其中包括一家已经签约的《财富》500 强客户。

Founded by Udith Vaidyanathan and Arun Ramakrishnan, LogicFlo represents a radically different vision for AI in regulated industries. In a space where ‘move fast and break things’ is a recipe for disaster, LogicFlo offers a new paradigm: move with precision. The platform gives every life sciences expert their own team of intelligent agents – AI collaborators designed to execute high-stakes, high-compliance tasks under human guidance, turning each specialist into the CEO of their own workflow..

由乌迪特·瓦伊迪亚纳坦和阿伦·拉马克里斯南创立的LogicFlo代表了受监管行业中AI应用的一种截然不同的愿景。在“快速行动，打破常规”可能引发灾难的领域，LogicFlo提供了一种新范式：以精准为驱动。该平台为每位生命科学专家配备了一支智能助手团队——这些AI协作者旨在人类指导下执行高风险、高合规性的任务，将每位专家转变为自身工作流程的主导者。

“While the rest of the world is focused on automation instead of people, we are building automation

“当世界其他地方都专注于自动化而不是人时，我们正在构建自动化解决方案”

for

为了

people,” said

“人们，”说

Udith Vaidyanathan, LogicFlo’s co-founder and CEO

乌迪特·瓦伊迪亚纳坦，LogicFlo联合创始人兼首席执行官

. “LogicFlo puts experts firmly at the center. The goal is to let the brightest people in life sciences do what only they can do – drive medical science forward and help elevate standard of care. ”

“LogicFlo将专家牢牢置于中心位置。其目标是让生命科学领域最聪明的人做只有他们才能做的事情——推动医学科学发展，帮助提升护理标准。”

Vaidyanathan previously steered key business units from inside Abbott’s CEO office before dropping out of Harvard Business School to build LogicFlo AI. Arun Ramakrishnan, co-founder and CTO, previously led deep learning efforts at Intuitive Surgical, where he built high-precision AI models for the Da Vinci robotic system deployed in real-world surgeries.

瓦伊迪亚纳坦之前在雅培公司首席执行官办公室内掌管过关键业务部门，之后他从哈佛商学院退学创建了LogicFlo AI。联合创始人兼首席技术官阿拉姆·拉马克里斯南曾领导直觉外科公司的深度学习工作，他在那里为实际手术中使用的达芬奇机器人系统构建了高精度的人工智能模型。

“Traditional automation has failed life sciences because it’s too rigid, too brittle, and too out of touch with how people actually work,” explained.

“传统自动化在生命科学领域失败了，因为它过于僵化、过于脆弱，且与人们实际工作方式脱节，”他解释道。

Ramakrishnan

拉马克里斯南

. “LogicFlo agents are different. They’re intelligent, composable, production-ready, and they understand the nuance of scientific work.”

“LogicFlo代理不同。它们智能化、可组合、可直接用于生产，并且能够理解科学工作的细微差别。”

LogicFlo marks a fundamental shift from systems of record to systems of engagement in enterprise software. While most life sciences software remains focused on platforms that store information but don’t do the work, LogicFlo introduces a layer where users interact directly with intelligent agents that can take instruction, act, and deliver results.

LogicFlo 代表了企业软件从记录系统到交互系统的基本转变。尽管大多数生命科学软件仍专注于存储信息但不执行操作的平台，LogicFlo 引入了一个层面，用户可以直接与智能代理交互，这些代理可以接受指令、采取行动并交付结果。

For the first time, work itself moves into a unified system of engagement, marking a paradigm shift in how knowledge work happens..

首次将工作本身纳入统一的参与系统，标志着知识工作方式的范式转变。

The platform is already deployed across medical affairs, regulatory, commercial, and quality teams at global pharmaceutical and medical device companies. Deployments typically begin with 20–30 active users and scale organically as teams experience the results. The impact is dramatic: medical writing outputs that took weeks now take minutes – with up to 2000x reduction in time to first draft – and response timelines for medical information requests have collapsed from 1-2 weeks to 1-2 days..

该平台已经在全球制药和医疗器械公司的医学事务、法规、商业和质量团队中部署。部署通常从20到30个活跃用户开始，并随着团队体验到成果后有机扩展。影响是显著的：原来需要数周才能完成的医学写作输出现在只需几分钟——初稿时间最多减少了2000倍——而且医学信息请求的响应时间已从1-2周缩短到1-2天。

Unlike brittle automation or black-box copilots, LogicFlo was built from day one for production use inside regulated environments. Every agent operates within a fully auditable, human-in-the-loop system. Agents are SOP-aware, organization-adapted, and trained to follow each company’s specific templates, workflows, and compliance requirements.

与脆弱的自动化或黑箱副驾不同，LogicFlo 从第一天起就为受监管环境中的生产使用而构建。每个代理都在一个完全可审计、人工参与的系统中运行。代理具备标准操作程序意识，适应组织，并经过培训以遵循每家公司的特定模板、工作流程和合规要求。

They collaborate as teams – breaking down work into subtasks, validating outputs, and escalating to human experts only when necessary..

他们以团队形式协作——将工作分解为子任务，验证输出结果，仅在必要时才提交给人类专家处理。

“We are at a once-in-a-generation inflection point,” added

“我们正处于一代人一次的拐点，”他补充道。

Vaidyanathan

瓦伊迪亚纳坦

. “For the first time, AI agents have reached a level of capability and control that makes meaningful productivity unlocks in regulated scientific work not only possible, but inevitable.”

“人工智能代理首次达到了一种能力和控制水平，这使得在受监管的科学工作中实现有意义的生产力突破不仅成为可能，而且不可避免。”

Rohil Bagga, VP Investments, Lightspeed

罗希·巴加，光速投资副总裁

, commented: “We’re thrilled to back LogicFlo AI as they revolutionize how life sciences and biotech organizations operate. Their AI agent platform empowers medical affairs and commercial teams to build agentic workflows across diverse use cases, dramatically boosting productivity. Founders Udith and Arun combine deep domain expertise with exceptional technical acumen—we’re excited to support them as they drive transformation in one of the world’s most critical industries.”.

，评论道：“我们非常高兴能够支持LogicFlo AI，因为他们正在革新生命科学和生物技术组织的运作方式。他们的AI代理平台使医学事务和商业团队能够在各种用例中构建代理工作流程，大幅提升生产力。创始人乌迪特和阿伦将深厚的领域专业知识与卓越的技术敏锐度相结合——我们期待在他们推动这一世界最关键行业的转型时给予支持。”

LogicFlo’s agents support functions across the entire life sciences value chain: medical writing with literature-based content creation and full referencing; Medical communications and information response generation with SR documents, material for ad boards, congresses, journal articles, commercial content creation with compliant promotional materials and MLR workflow management; regulatory authoring for CTAs, INDs, and safety narratives; quality and compliance documentation including SOPs, deviation reports, and CAPAs and so on..

LogicFlo的代理支持整个生命科学价值链中的功能：基于文献的医学写作与内容创作和完整引用；医学传播与信息响应生成，包括SR文档、广告委员会材料、会议、期刊文章、合规宣传材料的商业内容创作以及MLR工作流程管理；CTA、IND和安全性叙述的法规撰写；质量与合规文档，包括SOP、偏差报告、CAPA等。

With this new funding, LogicFlo will expand its agent libraries, deepen integrations with life-sciences native systems like Veeva and IQVIA, and grow its team to meet rising demand across the sector. The company’s vision extends beyond workflow optimization to redefining what work feels like for every expert in life sciences.

通过这笔新的资金，LogicFlo 将扩展其代理库，深化与生命科学原生系统（如 Veeva 和 IQVIA）的集成，并扩大团队以满足整个行业不断增长的需求。该公司的愿景不仅仅是工作流程优化，而是重新定义生命科学领域每位专家的工作体验。

“If we can give scientific experts a platform that moves at their speed, they’ll move science forward faster,” concluded .

“如果我们能为科学专家提供一个与他们速度相匹配的平台，他们将推动科学更快地向前发展，”总结道。

Vaidyanathan

瓦伊迪亚纳坦

.

。